We highlighted that TMSB10 may serve as a potential prognostic biomarker and immunotherapy target in glioma and that the knockdown of TMSB10 significantly improves the efficacy of selumetinib and anti-PD1 treatment, providing a theoretical basis for the development of more effective and targeted clinical treatment strategies for glioma patients. This evidence concerns the gene TMSB10 and glioma.